CRISPR Therapeutics AG CRSP reported fourth-quarter 2020 loss per share of $1.50, wider than the Zacks Consensus Estimate of a loss of $1.23.
Source link

Leave a Reply
You must be logged in to post a comment.
CRISPR Therapeutics AG CRSP reported fourth-quarter 2020 loss per share of $1.50, wider than the Zacks Consensus Estimate of a loss of $1.23.
Source link
You must be logged in to post a comment.